Patients with 5% or more bone marrow hematogones with repeat flow cytometry
| Clinical status . | Processing method and time sequence of studies . | Percent bone marrow hematogones . |
|---|---|---|
| Patient no. 1 | ||
| After chemotherapy for T-ALL | 1st analysis | 19% |
| DG-processed | ||
| After chemotherapy for T-ALL | 2nd analysis (3 wk later) | 11.5% |
| DG-processed | ||
| Patient no. 2 | ||
| Down syndrome | 1st analysis | 8.9% |
| Slowly evolving AML before treatment | AC-processed | |
| Down syndrome | 2nd analysis (3 wk later) | 10.2% |
| Slowly evolving AML before treatment | AC-processed | |
| Patient no. 3 | ||
| APL in remission after chemotherapy | 1st analysis | 6.2% |
| DG-processed | ||
| APL in remission after chemotherapy | 2nd analysis (4.5 mo later) | 2.6% |
| AC-processed | ||
| Patient no. 4 | ||
| ALL 14 d after induction chemotherapy | 1st analysis | 0% |
| DG-processed | ||
| 28 d after induction chemotherapy | 2nd analysis (2 wk later) | 0% |
| DG-processed | ||
| 2 mo after induction chemotherapy | 3rd analysis (1 mo later) | 0.5% |
| DG-processed | ||
| 3 mo after induction chemotherapy | 4th analysis (1 mo later) | 0.1% |
| AC-processed | ||
| 4 mo after induction chemotherapy | 5th analysis (1 mo later) | 6.6% |
| AC-processed | ||
| Patient no. 5 | ||
| NHL before treatment | 1st analysis | 6.6% |
| DG-processed | ||
| NHL 2.5 mo after chemotherapy | 2nd analysis (2.5 mo later) | 0.2% |
| AC-processed | ||
| Patient no. 6 | ||
| MDS before bone marrow transplantation | 1st analysis | 0.3% |
| DG-processed | ||
| After bone marrow transplantation | 2nd analysis (5.5 mo later) | 7.2% |
| AC-processed | ||
| Patient no. 7 | ||
| NHL before treatment | 1st analysis | 6.9% |
| DG-processed | ||
| NHL after chemotherapy | 2nd analysis (2.5 mo later) | 0.6% |
| DG-processed | ||
| Patient no. 8 | ||
| Residual AML after chemotherapy | 1st analysis | 0.19% |
| DG-processed | ||
| Residual AML after chemotherapy | 2nd analysis (1.5 mo later) | 1.7% |
| DG-processed | ||
| Residual AML after chemotherapy | 3rd analysis (1 mo later) | 9.3% |
| AC-processed | ||
| Residual AML after chemotherapy | 4th analysis (1 wk later) | 0% |
| AC-processed | ||
| Patient no. 9 | ||
| HIV and NHL after chemotherapy | 1st analysis | 10% |
| DG-processed | ||
| HIV and NHL after chemotherapy | 2nd analysis (2 mo later) | 0% |
| DG-processed |
| Clinical status . | Processing method and time sequence of studies . | Percent bone marrow hematogones . |
|---|---|---|
| Patient no. 1 | ||
| After chemotherapy for T-ALL | 1st analysis | 19% |
| DG-processed | ||
| After chemotherapy for T-ALL | 2nd analysis (3 wk later) | 11.5% |
| DG-processed | ||
| Patient no. 2 | ||
| Down syndrome | 1st analysis | 8.9% |
| Slowly evolving AML before treatment | AC-processed | |
| Down syndrome | 2nd analysis (3 wk later) | 10.2% |
| Slowly evolving AML before treatment | AC-processed | |
| Patient no. 3 | ||
| APL in remission after chemotherapy | 1st analysis | 6.2% |
| DG-processed | ||
| APL in remission after chemotherapy | 2nd analysis (4.5 mo later) | 2.6% |
| AC-processed | ||
| Patient no. 4 | ||
| ALL 14 d after induction chemotherapy | 1st analysis | 0% |
| DG-processed | ||
| 28 d after induction chemotherapy | 2nd analysis (2 wk later) | 0% |
| DG-processed | ||
| 2 mo after induction chemotherapy | 3rd analysis (1 mo later) | 0.5% |
| DG-processed | ||
| 3 mo after induction chemotherapy | 4th analysis (1 mo later) | 0.1% |
| AC-processed | ||
| 4 mo after induction chemotherapy | 5th analysis (1 mo later) | 6.6% |
| AC-processed | ||
| Patient no. 5 | ||
| NHL before treatment | 1st analysis | 6.6% |
| DG-processed | ||
| NHL 2.5 mo after chemotherapy | 2nd analysis (2.5 mo later) | 0.2% |
| AC-processed | ||
| Patient no. 6 | ||
| MDS before bone marrow transplantation | 1st analysis | 0.3% |
| DG-processed | ||
| After bone marrow transplantation | 2nd analysis (5.5 mo later) | 7.2% |
| AC-processed | ||
| Patient no. 7 | ||
| NHL before treatment | 1st analysis | 6.9% |
| DG-processed | ||
| NHL after chemotherapy | 2nd analysis (2.5 mo later) | 0.6% |
| DG-processed | ||
| Patient no. 8 | ||
| Residual AML after chemotherapy | 1st analysis | 0.19% |
| DG-processed | ||
| Residual AML after chemotherapy | 2nd analysis (1.5 mo later) | 1.7% |
| DG-processed | ||
| Residual AML after chemotherapy | 3rd analysis (1 mo later) | 9.3% |
| AC-processed | ||
| Residual AML after chemotherapy | 4th analysis (1 wk later) | 0% |
| AC-processed | ||
| Patient no. 9 | ||
| HIV and NHL after chemotherapy | 1st analysis | 10% |
| DG-processed | ||
| HIV and NHL after chemotherapy | 2nd analysis (2 mo later) | 0% |
| DG-processed |
T-ALL indicates T-cell acute lymphoblastic leukemia; DG, density gradient separation; AC, ammonium chloride lysis; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; NHL, non-Hodgkin lymphoma; HIV, human immunodeficiency virus; and MDS, myelodysplastic syndrome.